Divis Laboratories Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Nuvama has reiterated its Buy rating for Divis Laboratories, setting a target price of Rs 7,110. The company is positioned to benefit from Eli Lilly's Orforglipron, with potential revenue growth from its production capabilities.

Nuvama Reiterates Buy Rating for Divis Laboratories - 29 Aug, 2025

Divis Laboratories received a buy upgrade from Jefferies, raising its target price to Rs 7,150. Citigroup also maintains a buy rating at Rs 7,750. The stock gained up to 2.5%, reaching its highest level since August 6, driven by strong growth prospects and strategic positioning in the market.

Divis Laboratories Upgraded by Jefferies, Stock Rises - 25 Aug, 2025

Divis Laboratories shares increased by 3% following Citi's positive outlook, which highlighted attractive valuations and a price target of Rs 7,750, suggesting a buying opportunity amid recent stock weakness.

Citi's Buy Call Boosts Divis Laboratories Stock - 22 Aug, 2025

Divis Laboratories reported strong Q1 growth, but missed analyst estimates, leading to mixed reactions and target price revisions from various brokerages. Operational costs and pressures in the generics segment remain concerns, prompting some analysts to lower EPS estimates. Despite this, some brokerages maintain positive outlooks based on expected margin improvements and growth in custom synthesis contracts.

Divis Laboratories Faces Mixed Analyst Reactions Post Q1 Results - 07 Aug, 2025

Divis Laboratories announced Q1 FY26 results, reporting a net profit of ₹545 crore, missing estimates. Revenue rose 13.8% YoY but fell 6.79% QoQ, reflecting pricing pressures in the generics market.

Divis Laboratories Reports Q1 Results Below Expectations - 06 Aug, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

Mutual Funds have increased holdings from 12.83% to 13.31% in Jun 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Foreign Institutions have increased holdings from 18.01% to 19.74% in Jun 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 1 year, DIVISLAB stock has moved up by 20.8%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

In the last 3 years, Torrent Pharmaceuticals Ltd has given 135.6% return, outperforming this stock by 65.2%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 51.89% of holdings in Jun 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Revenue is down for the last 2 quarters, 2.67K Cr → 2.52K Cr (in ₹), with an average decrease of 5.3% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Netprofit is down for the last 2 quarters, 662.0 Cr → 545.0 Cr (in ₹), with an average decrease of 17.7% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Retail Investor have decreased holdings from 9.39% to 9.32% in Jun 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

NIFTY 100

Nifty Healthcare

Nifty Alpha 50

BSE 200

S&P BSE 100 LargeCap TMC

Nifty100 Eq Weig

NIFTY PHARMA

Nifty Next 50

BSE 100

S&P BSE SEN. N50

BSE Healthcare

S&P BSE 250 LargeMidCap

S&P BSE Dividend Stability

BSE 500

Nifty 500

S&P BSE Momentum

S&P BSE 100 ESG

Nifty100 Quality

S&P BSE Largecap

BSE MFG

Nifty 200

Nifty LargeMidcap 250

SBI Equity Hybrid Fund Direct Growth

SBI Large Cap Fund Direct Growth

SBI Focused Fund Direct Plan Growth

Axis ELSS Tax Saver Fund Direct Plan Growth Option

Nippon India Pharma Fund - Direct Plan - Growth Plan

Divis Laboratories Ltd’s net profit jumped 26.74% since last year same period to ₹545.00Cr in the Q1 2025-2026. On a quarterly growth basis, Divis Laboratories Ltd has generated -17.67% fall in its net profits since last 3-months.

Divis Laboratories Ltd Earnings Results

In the quarter ending March 2025, Divis Laboratories Ltd has declared dividend of ₹30.00 per share on 17 May 2025 - translating a dividend yield of 0.98%.

Name	Value	Action
MACD level (12,26)	0.29	Bearish
CCI (20)	-291.63	Bullish
RSI (14)	52.83	Neutral
Momentum (10)	-2.5	Bullish
ADI (14)	24.71	Neutral
Ultimate Oscillator (7,14,28)	63.37	Neutral

Name	Value	Action
SMA (20)	6166.6	Bearish
EMA (20)	6164.62	Bullish
VWMA (20)	6165.43	Bullish
SMA (50)	6161.34	Bullish
EMA (50)	6161.99	Bullish
SMA (200)	6151.74	Bullish
EMA (200)	6154.26	Bullish
KAMA (200)	6159.04	Bullish
DEMA (200)	6161.53	Bullish

Divis Laboratories Ltd (DIVISLAB)

Summary

Overall

Oscillators

Moving Averages